NCT01998893View on ClinicalTrials.gov

A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 1997

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

rituximab [MabThera/Rituxan]

375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse

Trial Locations (11)

30625

Hanover

37075

Göttingen

48129

Münster

50924

Cologne

66424

Homburg/saar

70376

Stuttgart

72076

Tübingen

79639

Grenzach-Wyhlen

80336

München

81377

München

91054

Erlangen

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01998893 - A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter